AGO Score
The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score was developed in an effort to predict operability in patients with a first recurrence of ovarian cancer.
Research authors: Andreas Du Bois, Philipp Harter
Details Formula Study characteristics Files & References
★★★
Model author
Model ID
2239
Version
1.36
Revision date
2020-06-10
MeSH terms
  • Ovarian Neoplasms
  • Locoregional Neoplasm Recurrence
  • Cytoreduction Surgical Procedure
  • Model type
    Linear model (Calculation)
    Status
    public
    Rating
    Share
    Formula

    Additional information

    The AGO-DESKTOP I study (Ann Surg Oncol. 2006;13(12):1702‐1710.) provided a score for the prediction of complete cytoreduction in recurrent ovarian cancer (ROC), which could predict complete resection to no gross residual disease (NGR) in 79% of patients. This AGO SCORE was then validated prospectively in the subsequent AGO-DESKTOP II study, showing it could predict 76% of patients who would benefit from Secondary Cytoreductive Surgery (SeCRS). (Int J Gynecol Cancer. 2011;21(2):289‐295.). Finally, the AGO-DESKTOP III trial was designed to evaluate in a prospectively randomized multicenter setting whether SeCRS followed by platinum-based combination chemotherapy can improve overall survival (OS) compared with platinum-based combination chemotherapy alone in AGO SCORE-positive patients with platinum-sensitive (platinum-free interval > 6 months) ROC (PSROC). (J Clin Oncol. 2020 38:15_suppl, 6000-6000) Accordingly, a patient’s selection for SeCRS by a positive AGO SCORE resulted in a meaningful survival benefit in terms of both OS and progression-free survival (PFS), but exclusively in those underwent SeCRS reaching NGR.

    Study Population

    Total population size: 267

    Additional characteristics

    No additional characteristics defined
    AGO Score
    V-1.36-2239.20.06.10
    Refer to Intended Use for instructions before use
    Evidencio B.V., Irenesingel 19, 7481 GJ, Haaksbergen, the Netherlands

    Related files

    No related files available

    Supporting Publications

    AGO score
    ...

    {{ resultSubheader }}

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Result
    Note
    Notes are only visible in the result download and will not be saved by Evidencio

    AGO score

    {{ resultSubheader }}
    {{ chart.title }}

    Outcome stratification

    Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

    Conditional information

    Result interpretation

    The AGO-DESKTOP I study (Ann Surg Oncol. 2006;13(12):1702‐1710.) provided a score for the prediction of complete cytoreduction in recurrent ovarian cancer (ROC), which could predict complete resection to no gross residual disease (NGR) in 79% of patients. This AGO SCORE was then validated prospectively in the subsequent AGO-DESKTOP II study, showing it could predict 76% of patients who would benefit from Secondary Cytoreductive Surgery (SeCRS). (Int J Gynecol Cancer. 2011;21(2):289‐295.). Finally, the AGO-DESKTOP III trial was designed to evaluate in a prospectively randomized multicenter setting whether SeCRS followed by platinum-based combination chemotherapy can improve overall survival (OS) compared with platinum-based combination chemotherapy alone in AGO SCORE-positive patients with platinum-sensitive (platinum-free interval > 6 months) ROC (PSROC). (J Clin Oncol. 2020 38:15_suppl, 6000-6000) Accordingly, a patient’s selection for SeCRS by a positive AGO SCORE resulted in a meaningful survival benefit in terms of both OS and progression-free survival (PFS), but exclusively in those underwent SeCRS reaching NGR (74.2% of patients in the AGO-DESKTOP III Study). (J Clin Oncol. 2020 38:15_suppl, 6000-6000) At the time of first relapse, 51% of patients with PSROC are AGO SCORE-positive according to AGO-DESKTOP II study, (Int J Gynecol Cancer. 2011;21(2):289‐295.) but these patients should also be comprehensively evaluated regarding their eligibility for SeCRS based on addictional imaging plus patients and tumor characteristics.

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments
    Rating
    Comment
    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
    logo

    Please sign in to enable Evidencio print features

    In order to use the Evidencio print features, you need to be logged in.
    If you don't have an Evidencio Community Account you can create your free personal account at:

    https://www.evidencio.com/registration

    Printed results - Examples {{ new Date().toLocaleString() }}


    Evidencio Community Account Benefits


    With an Evidencio Community account you can:

    • Create and publish your own prediction models.
    • Share your prediction models with your colleagues, research group, organization or the world.
    • Review and provide feedback on models that have been shared with you.
    • Validate your models and validate models from other users.
    • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
    • Use and save prediction models and their data.
    • Use patient specific protocols and guidelines based on sequential models and decision trees.
    • Stay up-to-date with new models in your field as they are published.
    • Create your own lists of favorite models and topics.
    A personal Evidencio account is free, with no strings attached! Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

    Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.